MA45680A - Protéines de liaison bispécifiques de type anticorps se liant spécifiquement à cd3 et cd123 - Google Patents

Protéines de liaison bispécifiques de type anticorps se liant spécifiquement à cd3 et cd123

Info

Publication number
MA45680A
MA45680A MA045680A MA45680A MA45680A MA 45680 A MA45680 A MA 45680A MA 045680 A MA045680 A MA 045680A MA 45680 A MA45680 A MA 45680A MA 45680 A MA45680 A MA 45680A
Authority
MA
Morocco
Prior art keywords
bispecific antibody
proteins specifically
binding
type
binding proteins
Prior art date
Application number
MA045680A
Other languages
English (en)
Inventor
Jana Albrecht
Christian Beil
Jochen Beninga
Stéphane Guerif
Katja Kroll
Christian Lange
Wulf Dirk Leuschner
Ercole Rao
Marion Schneider
Peter Wonerow
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA45680A publication Critical patent/MA45680A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
MA045680A 2016-07-18 2017-07-17 Protéines de liaison bispécifiques de type anticorps se liant spécifiquement à cd3 et cd123 MA45680A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16305923 2016-07-18

Publications (1)

Publication Number Publication Date
MA45680A true MA45680A (fr) 2019-05-22

Family

ID=56507555

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045680A MA45680A (fr) 2016-07-18 2017-07-17 Protéines de liaison bispécifiques de type anticorps se liant spécifiquement à cd3 et cd123

Country Status (24)

Country Link
US (1) US20190241657A1 (fr)
EP (1) EP3484924A1 (fr)
JP (2) JP7071329B2 (fr)
KR (1) KR20190028771A (fr)
CN (1) CN109715665A (fr)
AR (1) AR109264A1 (fr)
AU (1) AU2017299125A1 (fr)
BR (1) BR112019000770A2 (fr)
CA (1) CA3030943A1 (fr)
CL (1) CL2019000119A1 (fr)
CO (1) CO2019001367A2 (fr)
CR (1) CR20190072A (fr)
DO (1) DOP2019000011A (fr)
EA (1) EA201990321A1 (fr)
EC (1) ECSP19011185A (fr)
IL (1) IL264248A (fr)
MA (1) MA45680A (fr)
MX (1) MX2019000844A (fr)
PE (1) PE20190514A1 (fr)
PH (1) PH12019500122A1 (fr)
SG (1) SG11201900400QA (fr)
TN (1) TN2019000015A1 (fr)
TW (1) TWI790206B (fr)
WO (1) WO2018015340A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2824167T3 (es) 2015-01-23 2021-05-11 Sanofi Sa Anticuerpos anti-CD3, anticuerpos anti-CD123 y anticuerpos biespecíficos que se unen específicamente a CD3 y/o CD123
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
JP2022513402A (ja) * 2018-10-30 2022-02-07 マクロジェニクス，インコーポレーテッド 血液悪性腫瘍の治療のための二重特異性ｃｄ１２３×ｃｄ３ダイアボディ
MA55305A (fr) * 2019-03-11 2022-01-19 Janssen Biotech Inc Anticorps bispécifiques anti-v béta 17/anti-cd123
CN111349163A (zh) 2020-02-05 2020-06-30 北京智仁美博生物科技有限公司 针对cd123的单克隆抗体
TW202200618A (zh) * 2020-03-17 2022-01-01 美商西雅圖免疫公司 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法
US11965024B2 (en) 2020-09-11 2024-04-23 Janssen Biotech, Inc. Methods and compositions for modulating beta chain mediated immunity
WO2022165171A1 (fr) 2021-01-28 2022-08-04 Regeneron Pharmaceuticals, Inc. Compositions et méthodes de traitement du syndrome de libération de cytokines
CN113368232B (zh) * 2021-06-02 2022-08-26 上海交通大学 多特异性抗原结合蛋白及其应用
CA3224408A1 (fr) * 2021-08-06 2023-02-09 Rosalba LEPORE Variants de proteine de surface cellulaire discernables destines a etre utilises en therapie cellulaire
US20230357446A1 (en) 2022-04-11 2023-11-09 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
EP0272253A4 (fr) 1986-03-07 1990-02-05 Massachusetts Inst Technology Procede pour ameliorer la stabilite des glycoproteines.
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
DE69032484D1 (de) 1989-10-27 1998-08-20 Arch Dev Corp Zusammensetzungen und deren verwendung zur förderung der immunopotentiation
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
DE69131017T2 (de) 1990-12-20 1999-07-15 Ixsys Inc Optimierung von bindenden proteinen
CA2156725A1 (fr) 1993-02-22 1994-09-01 Warren S. Pear Production de retrovirus sans auxiliaire, a haut titre, par transfection transitoire
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
JP3946256B2 (ja) 1995-09-11 2007-07-18 協和醗酵工業株式会社 ヒトインターロイキン５受容体α鎖に対する抗体
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6177078B1 (en) 1995-12-29 2001-01-23 Medvet Science Pty Limited Monoclonal antibody antagonists to IL-3
DE19721700C1 (de) 1997-05-23 1998-11-19 Deutsches Krebsforsch Mutierter OKT3-Antikörper
PT1071752E (pt) 1998-04-21 2003-11-28 Micromet Ag Polipeptidos especificos para cd19xcd3 e suas utilizacoes
AU5003001A (en) 2000-03-06 2001-09-17 Univ Kentucky Res Found Methods to impair hematologic cancer progenitor cells and compounds related thereto
CA2698203C (fr) 2007-08-29 2018-09-11 Sanofi-Aventis Anticorps anti-cxcr5 humanises, leurs derives et leurs utilisations
EP2050764A1 (fr) 2007-10-15 2009-04-22 sanofi-aventis Nouveau format d'anticorps bispécifique polyvalent
RU2547600C2 (ru) * 2008-10-01 2015-04-10 Эмджен Рисерч (Мьюник) Гмбх Pscaxcd3, cd19xcd3, c-metxcd3, эндосиалинxcd3, epcamxcd3, igf-1rxcd3 или fap-альфаxcd3 биспецифическое одноцепочечное антитело с межвидовой специфичностью
TWI622597B (zh) 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
CN103748114B (zh) 2011-08-23 2017-07-21 罗切格利卡特公司 T细胞活化性双特异性抗原结合分子
EP4053162A1 (fr) * 2012-05-18 2022-09-07 Aptevo Research and Development LLC Immunofusion bispécifique (ifb) de scfv se liant au cd123 et cd3
EP2839842A1 (fr) * 2013-08-23 2015-02-25 MacroGenics, Inc. Bianticorps monovalents bi-spécifiques capables de se lier aux CD123 et CD3 et leurs utilisations
CN105793285A (zh) * 2013-12-10 2016-07-20 豪夫迈·罗氏有限公司 多亚基结构的亚基的结合结构域用于将药物活性实体靶向递送至多亚基结构的用途
EA037647B1 (ru) 2014-09-05 2021-04-27 Янссен Фармацевтика Нв Агенты, связывающиеся с cd123, и виды их применения
CA2967426A1 (fr) * 2014-11-26 2016-06-02 Xencor, Inc. Anticorps heterodimeriques se liant a l'antigene cd3 et a un antigene tumoral
ES2824167T3 (es) * 2015-01-23 2021-05-11 Sanofi Sa Anticuerpos anti-CD3, anticuerpos anti-CD123 y anticuerpos biespecíficos que se unen específicamente a CD3 y/o CD123

Also Published As

Publication number Publication date
EA201990321A1 (ru) 2019-06-28
TN2019000015A1 (en) 2020-07-15
US20190241657A1 (en) 2019-08-08
SG11201900400QA (en) 2019-02-27
MX2019000844A (es) 2019-07-04
TWI790206B (zh) 2023-01-21
AU2017299125A1 (en) 2019-03-07
DOP2019000011A (es) 2019-05-15
IL264248A (en) 2019-02-28
CO2019001367A2 (es) 2019-02-19
PH12019500122A1 (en) 2019-04-15
EP3484924A1 (fr) 2019-05-22
JP2022105138A (ja) 2022-07-12
ECSP19011185A (es) 2019-02-28
JP7071329B2 (ja) 2022-05-18
AR109264A1 (es) 2018-11-14
CR20190072A (es) 2019-06-25
WO2018015340A1 (fr) 2018-01-25
CN109715665A (zh) 2019-05-03
CA3030943A1 (fr) 2018-01-25
CL2019000119A1 (es) 2019-06-14
KR20190028771A (ko) 2019-03-19
JP2019531701A (ja) 2019-11-07
PE20190514A1 (es) 2019-04-10
BR112019000770A2 (pt) 2019-07-02
TW201811830A (zh) 2018-04-01

Similar Documents

Publication Publication Date Title
MA45680A (fr) Protéines de liaison bispécifiques de type anticorps se liant spécifiquement à cd3 et cd123
MA54514A (fr) Anticorps se liant à cd3
MA51734A (fr) Anticorps se liant à gprc5d
MA49038A (fr) Anticorps bispécifiques se liant particulièrement à pd1 et lag3
MA43305A (fr) Anticorps hétérodimériques se liant aux antigènes cd3 et cd38
CY1123236T1 (el) Αντισωματα διπλης εξειδικευσης που δεσμευονται με cd38 και cd3
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
MA41279A (fr) Anticorps hétérodimériques se liant aux antigènes cd3 et tumoraux
MA46893A (fr) Anticorps bispécifiques se liant au facteur ix de coagulation et au facteur x de coagulation
ECSP18000844A (es) Anticuerpos de unión a tau
KR102355950B9 (ko) Tigit에 대한 항체
MA41313A (fr) Anticorps de liaison de la protéine april modifiés
MA43874A (fr) Constructions de liaison à l'antigène immunomodulateur multispécifique
MA42626A (fr) Nouveaux anticorps anti-pd-1
CL2016000460A1 (es) Proteínas de unión al antígeno gitr
MA50505A (fr) Anticorps 2 + 1 bispécifiques (contorsbodies)
MA42808A (fr) Anticorps de liaison à l'il-8 et leurs utilisations
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
MA55347A (fr) Anticorps anti-lag3 et fragments de fixation à l'antigène
MA46917A (fr) Anticorps anti-met, molécules de liaison à un antigène bispécifique se liant à met, et leurs procédés d'utilisation
ECSP18000887A (es) Anticuerpos de unión a tau
MA44072A (fr) Anticorps se liant spécifiquement à hla-dr et leurs utilisations
DK3164159T3 (da) Bispecifikke cd33- og cd3-bindende proteiner
DK3137504T3 (da) Antistofbinding til fcrn til behandling af autoimmunsygdomme
MA42821A (fr) Protéines de liaison à l'antigène tétraspécifiques et bispécifiques tétravalentes et utilisations de celles-ci